FDA cleared Datroway (datopotamab deruxtecan-dlnk) on May 22 as the first TROP2-directed antibody-drug conjugate for first-line metastatic triple-negative breast cancer in patients who aren’t candidates for PD-1 or PD-L1 inhibitor therapy. That’s a hard-to-treat population, and Daiichi Sankyo and AstraZeneca now own it outright.
The data behind the nod is hard to argue with. In the TROPION-Breast02 Phase 3 trial across 644 patients, Datroway hit 23.7 months median overall survival versus 18.7 months on chemotherapy. Progression-free survival: 10.8 months versus 5.6 months, a 43% risk reduction. Overall response rate came in at 64% versus 30%. It’s the first targeted therapy to show a statistically significant OS advantage over chemo in this setting.
AstraZeneca bet big on this molecule early. The collaboration with Daiichi Sankyo, inked in July 2020, cost AZ $1 billion upfront with up to $5 billion in regulatory and sales milestones attached. Datroway posted roughly $300 million in sales during Daiichi’s 2025 fiscal year; the company is targeting more than double that in 2026. AstraZeneca has a $5 billion peak sales target on Datroway — and this TNBC approval, covering an estimated 70% of metastatic TNBC patients ineligible for immunotherapy, is the clearest path to getting there.
The competitive read matters here. Gilead’s Trodelvy, the closest TROP2 competitor, failed to hit statistical significance on overall survival in Ascent-03, its own first-line TNBC trial. Gilead isn’t out of the game: Ascent-04, combining Trodelvy with Keytruda in PD-L1-positive patients, has an FDA decision expected in the second half of 2026, but Daiichi and AZ got to the front-line label first. In ADC oncology, first-mover advantage compounds fast.
The next milestone to watch: Gilead’s Ascent-04 readout, expected H2 2026.
— Sarah Chen